Boulton, A.P.R. and Shen, Y. (2022), Anti-interleukin-4 or -13 agents for treating asthma. Clin Exp Allergy. https://doi.org/10.1111/cea.14242
Key Messages
- Patients with severe asthma may have inadequate responses to therapies targeting immunoglobulin E and interleukin-5.
- Anti-IL-13 and/or -4 agents reduced asthma exacerbations requiring hospitalization or emergency services.
- Improvements in asthma-related quality of life and asthma control are unlikely to be clinically significant.